Efficacy of sequential administration of G-SCF and GM-CSF after antitumor chemotherapy in patients with advanced cancer: Results of a randomized study;Efficacia della somministrazione sequenziale di G-CSF e GM-CSF dopo chemioterapia antitumorale in pazienti in fase avanzata: Risultati di uno studio randomizzato

Tumori

Volumn 83, Issue 5 SUPPL., 1997, Pages

  Mustacchi, Giorgio ^a   Ceccherini, Rita ^a   Milani, Silvia ^a   Sandri, Paolo ^a   Leita, Maria Livia ^a   Carbonara, Teresa ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

G CSF; GM CSF; Highly myelodepressive chemotherapy; Sequential combination

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL;

ADULT; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MELANOMA; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SINGLE BLIND PROCEDURE; STOMACH CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0031408548     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Both F.J., Van Eijk L., Schipper P., Backx B., Loewenberg B.: Synergistic effects between GM-CSF and G-CSF or M-CSF on highly enriched human marrow progenitor cells. Leukemia, 4: 325-328, 1990.
2. Danova M., Giordano M., Alberici R., Ucci G., Mazzini G., Riccardi A., Ascari E.: In vivo cytokinetic effects of G-CSF/IL3 and G-CSF/GM-CSF on hematopoietic progenitors during multicyclic, dose-intensive chemotherapy. Proc. ASCO; 15, 734, pp 274, 1996.
3. Danova M., Rosti V., Mazzini G., Ucci G., Mazzini G., Riccardi A., Ascari E.: Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. Int. J. Cancer, 63: 646-651, 1995.
4. Demetri G.D.: Evolution and uses of newer hematopoietic cytokines and cytokine combinations. 29th ASCO Meeting Educational Book, pp 44-49, 1993.
5. Dexter T.M.: Synergistic interactions in hemopoiesis biological implications and clinical use. Eur. J. Cancer, 29A, (Suppl 3): S6-S9, 1993.
6. Leary A.G., Hai Q.Z., Clark S.C., Ogawa M.: Growth factor requirements for survival in GO and entry into the cell cycle of primitive human hemopoietic progenitors. Proc. Natl. Acad. Sci. USA, 89, 9: 4013-4017, 1992.
7. Metcalf D.: Hematopoietic regulators: redundancy or subtlety? Blood, 82: 3515-3523, 1993.
8. Miller A.B.: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
9. Miller L.L.: The therapeutic utility of G-and GM-CSF in counteracting the bone marrow suppression of chemo-and radiotherapy. 29th ASCO Meeting Educational Book, pp 34-43, 1993.
10. 35th World Medical Assembly. The Declaration of Helsinki, Venezia October 1983 and subsequent modifications, Hong Kong, September 1989.